A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Antiviral Activity of a Single Intravenous Dose of VIS410 in Healthy Subjects after a Viral Inoculation with Influenza A (H1N1)

Trial Profile

A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Antiviral Activity of a Single Intravenous Dose of VIS410 in Healthy Subjects after a Viral Inoculation with Influenza A (H1N1)

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs VIS 410 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Visterra
  • Most Recent Events

    • 24 Aug 2016 According to Visterra media release, efficacy, resistance testing, and pharmacokinetic results from this study will be presented at the Options IX for the Control of Influenza Conference.
    • 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
    • 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top